Mink therapeutics to participate at upcoming investor conferences

New york, aug. 31, 2022 (globe newswire) -- mink therapeutics, inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, announced that the company will participate in two investor conferences in september:
INKT Ratings Summary
INKT Quant Ranking